Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celebrex, Bextra Documents Requested By SEC

This article was originally published in The Pink Sheet Daily

Executive Summary

SEC investigation joins ongoing investigations by Department of Justice, state attorneys general and a civil suit issued by the State of Louisiana.

You may also be interested in...

Bextra Withdrawal Costs Pfizer $1.28 Bil. In First Quarter

Pfizer will have to take charges to write off assets relating to the withdrawal of the COX-2 inhibitor in addition to $71 mil. in expected product returns. Pfizer has revised its April 5 guidance downward to reflect the withdrawal.

SEC Initiates Formal Investigation Into Vioxx Withdrawal

Escalation of SEC's "informal inquiry" is "not unexpected," Merck says. Company anticipates a federal judicial panel will rule in several weeks on motions to consolidate Vioxx personal injury and shareholder lawsuits for coordinated pretrial proceedings.

Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly

Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts